A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations

The factor VIII (FVIII)-neutralizing antibody (inhibitor) seen in 25%–30% of patients with severe haemophilia A (SHA). Vaccination is a non-genetic risk factor of inhibitor development as ‘danger signal’ which may provide a pro-inflammatory microenvironment to increase FVIII immunogenicity. We repor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Immunopathol Pharmacol
Hlavní autoři: Li, Zekun, Chen, Zhenping, Cheng, Xiaoling, Wu, Xinyi, Li, Gang, Zhen, Yingzi, Poon, Man-Chiu, Wu, Runhui
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2020
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7338642/
https://ncbi.nlm.nih.gov/pubmed/32627611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2058738420934618
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky